Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).

被引：0
|
作者：
Cavo, Michele
Iida, Shinsuke
Blade, Joan
Mateos, Maria-Victoria
Lee, Je-Jung
Garg, Mamta
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8031
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
    Zeng, Xiaohui
    Liu, Qiao
    Peng, Liubao
    Peng, Ye
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Wan, Xiaomin
    Tan, Chongqing
    ADVANCES IN THERAPY, 2021, 38 (05) : 2379 - 2390
  • [42] Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
    Xiaohui Zeng
    Qiao Liu
    Liubao Peng
    Ye Peng
    Lidan Yi
    Xia Luo
    Sini Li
    Xiaomin Wan
    Chongqing Tan
    Advances in Therapy, 2021, 38 : 2379 - 2390
  • [43] Phase III trial evaluating bortezomib in addition to melphalan/prednisone in newly diagnosed patients ineligible for transplantation
    Muneer, Sabeeha
    Cunningham, Sonia
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (01): : 18 - 20
  • [44] Daratumumab Bortezomib and Dexamethasone in Transplant Ineligible Newly Diagnosed Elderly Myeloma Patients - a Trial By Asian Myeloma Network
    Nagarajan, Chandramouli
    Tan, Melinda
    Chen, Yunxin
    Ooi, Melissa
    De Mel, Sanjay
    Tso, Allison
    Ng, Lawrence
    Than, Hein
    Goh, Yeow Tee
    Durie, Brian G. M.
    Chng, Wee-Joo
    BLOOD, 2023, 142
  • [45] PROGRESSION-FREE SURVIVAL (PFS) WITH DARATUMUMAB- BORTEZOMIB-MELPHALAN-PREDNISONE (D-VMP) COMBINATION THERAPY AND ALTERNATIVE TREATMENTS FOR PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA (MM) INELIGIBLE FOR STEM CELL TRANSPLANTATION (ASCT): A PARAMETRIC NETWORK META-ANALYSIS (PNMA)
    van Beekhuizen, S.
    Pisini, M.
    Otero, Gros B.
    Gaudig, M.
    Heeg, B.
    VALUE IN HEALTH, 2019, 22 : S103 - S103
  • [46] Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) Is the Optimal Combination for Patients with Newly Diagnosed Multiple Myeloma (MM) Patients Between 65 and 80 Years
    Mateos, Maria-Victoria
    Martinez-Lopez, Joaquin
    Hernandez, Miguel T.
    Ocio, Enrique M.
    Rosinol, Laura
    Martinez, Rafael
    Teruel, Ana Isabel
    Gutierrez, Norma C.
    Martin, Maria-Luisa
    Oriol, Albert
    Bargay, Joan
    Bengoechea, Enrique
    Gonzalez, Yolanda
    Perez de Oteyza, Jaime
    Gironella, Mercedes
    Encinas, Cristina
    Cabrera, Carmen
    Paiva, Bruno
    Teresa Cedena, Maria
    Puig, Noemi
    Blade, Joan
    Jose Lahuerta, Juan
    San Miguel, Jesus
    BLOOD, 2015, 126 (23)
  • [47] Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial
    Mateos, Maria-Victoria
    Martinez-Lopez, Joaquin
    Hernandez, Miguel-T
    Martinez, Rafael
    Rosinol, Laura
    Ocio, Enrique M.
    Asuncion Echeveste, Maria
    Perez de Oteyza, Jaime
    Oriol, Albert
    Bargay, Joan
    Gironella, Mercedes
    Martin, Jesus
    Cabrera, Carmen
    De La Rubia, Javier
    Gutierrez, Norma C.
    Martin, Maria-Luisa
    Paiva, Bruno
    Angeles Montalban, Maria
    Blade, Joan
    Jose Lahuerta, Juan
    San Miguel, Jesus F.
    BLOOD, 2014, 124 (21)
  • [48] Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
    Usmani, S. Z.
    Cavenagh, J. D.
    Belch, A. R.
    Hulin, C.
    Basu, S.
    White, D.
    Nooka, A.
    Ervin-Haynes, A.
    Yiu, W.
    Nagarwala, Y.
    Berger, A.
    Pelligra, C. G.
    Guo, S.
    Binder, G.
    Gibson, C. J.
    Facon, T.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (03) : 243 - 258
  • [49] Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial
    Fujisaki, Tomoaki
    Ishikawa, Takayuki
    Takamatsu, Hiroyuki
    Suzuki, Kenshi
    Min, Chang-Ki
    Lee, Jae Hoon
    Wang, Jianping
    Carson, Robin
    Crist, Wendy
    Qi, Ming
    Nagafuji, Koji
    ANNALS OF HEMATOLOGY, 2019, 98 (12) : 2805 - 2814
  • [50] Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial
    Tomoaki Fujisaki
    Takayuki Ishikawa
    Hiroyuki Takamatsu
    Kenshi Suzuki
    Chang-Ki Min
    Jae Hoon Lee
    Jianping Wang
    Robin Carson
    Wendy Crist
    Ming Qi
    Koji Nagafuji
    Annals of Hematology, 2019, 98 : 2805 - 2814
12345